Background: Recent studies have shown that pretreatment inflammatory responses can predict prognosis. However, no reports have analyzed the combined effect of the inflammatory response with pre-treatment and post-neo adjuvant chemotherapy (NACT). This retrospective study aims to identify factors predicting prognosis and create a novel predictive scoring system. Methods: The study was conducted at our institution between June 2006 and March 2020. Demographic and clinicopathological data were collected from patients with advanced epithelial ovarian cancer who underwent neoadjuvant chemotherapy after sample collection by laparoscopic or laparotomy surgery, followed by interval debulking surgery. We created a scoring system, called the Predictive Prognosis Score around NACT (PPSN), using factors extracted from a receiver operating characteristic curve analysis. Univariate and multivariate analyses were conducted to assess the efficacy of PPSN in predicting progression-free survival and overall survival. Kaplan-Meier and log-rank tests were used to compare the PFS or OS rate. Results: Our study included 72 patients, with a cut-off value of four for the scoring system. Our analysis showed that high PPSN (≥4) significantly predicts poor prognosis. Moreover, CD3+and CD8+tumor-infiltrating lymphocytes with low PPSN (<4) showed higher aggregation than those with high PPSN (≥4) cases. Conclusion: Our study shows that PPSN could be a useful prognostic tool for advanced EOC patients who undergo NACT followed by IDS.
背景：近期研究表明，治疗前炎症反应可预测预后，但目前尚无研究分析炎症反应与新辅助化疗（NACT）前后治疗阶段的联合效应。本回顾性研究旨在识别预后预测因素，并构建新型预测评分系统。方法：本研究于2006年6月至2020年3月在本机构开展，收集经腹腔镜或开腹手术取样后接受新辅助化疗、继而行间歇性肿瘤细胞减灭术的晚期上皮性卵巢癌患者的人口统计学与临床病理学数据。通过受试者工作特征曲线分析提取相关因素，构建名为“新辅助化疗预后预测评分”（PPSN）的评分系统。采用单变量与多变量分析评估PPSN对无进展生存期和总生存期的预测效能，并通过Kaplan-Meier法与对数秩检验比较无进展生存率或总生存率。结果：本研究纳入72例患者，评分系统截断值为4分。分析显示高PPSN（≥4分）可显著预测不良预后。此外，低PPSN（<4分）患者的CD3+与CD8+肿瘤浸润淋巴细胞聚集程度显著高于高PPSN（≥4分）患者。结论：研究表明PPSN可作为接受新辅助化疗联合间歇性肿瘤细胞减灭术治疗的晚期上皮性卵巢癌患者有效的预后评估工具。
肿瘤(癌症)患者之家